Cryotherapy + Imiquimod Active in Cutaneous Metastases of Melanoma

This article originally appeared here.
Cryotherapy + Imiquimod Active in Cutaneous Melanoma Mets
Cryotherapy + Imiquimod Active in Cutaneous Melanoma Mets

HealthDay News — Cryotherapy combined with topical imiquimod 5% is an active treatment for locoregional cutaneous metastases of melanoma (LCMM), according to research published online Dec. 12 in the Journal of Dermatology.

Noting that treatment of LCMM represents a therapeutic challenge, Nancy Rivas-Tolosa, MD, from the Instituto Valenciano de Oncología in Valencia, Spain, and colleagues evaluated the efficacy of the combination of cryotherapy and topical imiquimod 5% for treating the disease. The authors documented the locoregional cutaneous response to the treatment in 20 patients diagnosed with LCMM.

The researchers found that 65% of patients responded to treatment after a mean of five sessions: 40% with complete response and 25% with partial response. In 80% of patients, systemic disease progressed.

"Cryotherapy followed by topical imiquimod 5% is simple to apply, has minimal adverse effects, and provides response rates similar to other, more complex treatment options," the authors write.

Abstract
Full Text (subscription or payment may be required)

Loading links....